Sandoz submits ANDA for Pemigatinib, seeking FDA approval
Sandoz Inc. has submitted an Abbreviated New Drug Application (ANDA) for Pemigatinib, currently under standard review.
Company
Sandoz
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
Sandoz's submission of an ANDA for Pemigatinib signals an impending increase in market competition, which could affect pricing and market share for existing therapies. Portfolio teams need to closely monitor the FDA's review process and competitor responses to effectively strategize.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any potential responses from competitors regarding market entry strategies.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.